Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

L.J.M. Mekenkamp; J Tol; J.R. Dijkstra; I. de Krijger; M.E. Vink-Borger; S. van Vliet; S. Teerenstra; E.J. Kamping; E.T. Verwiel; M. Koopman; G.A. Meijer; J.H. van Krieken; C.J Punt; I.D.. Nagtegaal

doi:10.1186/1471-2407-12-292

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

Translated title of the contribution: Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

L.J.M. Mekenkamp
, J Tol
, J.R. Dijkstra
, I. de Krijger
, M.E. Vink-Borger
, S. van Vliet
, S. Teerenstra
, E.J. Kamping
, E.T. Verwiel
, M. Koopman
, G.A. Meijer
, J.H. van Krieken
, C.J Punt
, I.D.. Nagtegaal

Research output: Contribution to journal › Article › Academic › peer-review

Translated title of the contribution	Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.
Original language	Undefined/Unknown
Pages (from-to)	292
Number of pages	1
Journal	BMC Cancer
Volume	12
DOIs	https://doi.org/10.1186/1471-2407-12-292
Publication status	Published - 2012

Access to Document

10.1186/1471-2407-12-292

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3508829/

Cite this

Mekenkamp, L. J. M., Tol, J., Dijkstra, J. R., de Krijger, I., Vink-Borger, M. E., van Vliet, S., Teerenstra, S., Kamping, E. J., Verwiel, E. T., Koopman, M., Meijer, G. A., van Krieken, J. H., Punt, C. J., & Nagtegaal, I. D. (2012). Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients. BMC Cancer, 12, 292. https://doi.org/10.1186/1471-2407-12-292

@article{926469edc5c54107bb760c4d46ddd65f,

title = "Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.",

author = "L.J.M. Mekenkamp and J Tol and J.R. Dijkstra and \{de Krijger\}, I. and M.E. Vink-Borger and \{van Vliet\}, S. and S. Teerenstra and E.J. Kamping and E.T. Verwiel and M. Koopman and G.A. Meijer and \{van Krieken\}, J.H. and C.J Punt and I.D.. Nagtegaal",

year = "2012",

doi = "10.1186/1471-2407-12-292",

language = "Undefined/Unknown",

volume = "12",

pages = "292",

journal = "BMC Cancer",

issn = "1471-2407",

publisher = "BioMed Central Ltd.",

}

Mekenkamp, LJM, Tol, J, Dijkstra, JR, de Krijger, I, Vink-Borger, ME, van Vliet, S, Teerenstra, S, Kamping, EJ, Verwiel, ET, Koopman, M, Meijer, GA, van Krieken, JH, Punt, CJ & Nagtegaal, ID 2012, 'Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.', BMC Cancer, vol. 12, pp. 292. https://doi.org/10.1186/1471-2407-12-292

TY - JOUR

T1 - Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients.

AU - Mekenkamp, L.J.M.

AU - Tol, J

AU - Dijkstra, J.R.

AU - de Krijger, I.

AU - Vink-Borger, M.E.

AU - van Vliet, S.

AU - Teerenstra, S.

AU - Kamping, E.J.

AU - Verwiel, E.T.

AU - Koopman, M.

AU - Meijer, G.A.

AU - van Krieken, J.H.

AU - Punt, C.J

AU - Nagtegaal, I.D..

PY - 2012

Y1 - 2012

U2 - 10.1186/1471-2407-12-292

DO - 10.1186/1471-2407-12-292

M3 - Article

C2 - 22804917

SN - 1471-2407

VL - 12

SP - 292

JO - BMC Cancer

JF - BMC Cancer

ER -